In a phase II randomized, double‐blind, placebo‐controlled trial, a single 750 mg infusion of Lu AG09222, a humanized monoclonal antibody targeting PACAP, was administered to adults with migraine who had failed two to four prior preventive therapies. The gene discussed is ADCYAP1; the disease is migraine disorder.